News & Updates

Treatment with dupilumab results in significant improvements in the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adult Asian patients without any serious adverse effects, a Singapore study has shown.

The use of dupilumab significantly delays disease relapse in patients with moderate-to-severe atopic dermatitis (AD) while having an acceptable safety profile, reports a study.

Treatment with seladelpar for up to 2 years improves cholestatic biomarkers and pruritus in patients with primary biliary cholangitis (PBC), with no serious safety concerns noted with long-term use, as shown by interim results of the ASSURE study.